Photo of Bruce A. Chabner,  MD

Bruce A. Chabner, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-3200
Fax: (617) 643-2683

Bruce A. Chabner, MD

Massachusetts General Hospital


  • Professor, Medicine, Harvard Medical School
  • Director of Clinical Research, MGH Cancer Center, Massachusetts General Hospital



  • Member, Clinical Science Coordinating Committee

Research Abstract

Major interest is in the clinical testing, pharmaco-kinetics, and biochemical pharacology of new anticancer drugs, particulary natural products and signal transdution inhibitors.


Powered by Harvard Catalyst
  • Gainor JF, Chabner BA. Ponatinib: Accelerated Disapproval. Oncologist 2015. PubMed
  • Percac-Lima S, Cronin PR, Ryan DP, Chabner BA, Daly EA, Kimball AB. Patient navigation based on predictive modeling decreases no-show rates in cancer care. Cancer 2015. PubMed
  • Chabner BA. Defining a New Role for the National Cancer Institute Cooperative Groups: More Science, Fewer Trials. Oncologist 2014. PubMed
  • Efstathiou JA, Bvochora-Nsingo M, Gierga DP, Alphonse Kayembe MK, Mmalane M, Russell AH, Paly JJ, Brown C, Musimar Z, Abramson JS, Bruce KA, Karumekayi T, Clayman R, Hodgeman R, Kasese J, Makufa R, Bigger E, Suneja G, Busse PM, Randall TC, Chabner BA, Dryden-Peterson S. Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership. Int J Radiat Oncol Biol Phys 2014; 89:468-75. PubMed
  • Chabner BA. Approval after phase I: ceritinib runs the three-minute mile. Oncologist 2014; 19:577-8. PubMed
  • Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res 2014; 20:2587-94. PubMed
  • Chabner BA. Effective double whammy targets DNA synthesis in leukemia. J Exp Med 2014; 211:384. PubMed
  • Chabner BA, Ellisen LW, Iafrate AJ. Personalized medicine: hype or reality. Oncologist 2013; 18:640-3. PubMed
  • Percac-Lima S, Benner CS, Lui R, Aldrich LS, Oo SA, Regan N, Chabner BA. The impact of a culturally tailored patient navigator program on cervical cancer prevention in latina women. J Womens Health (Larchmt) 2013; 22:426-31. PubMed
  • Chabner BA, Efstathiou J, Dryden-Peterson S, . Cancer in Botswana: the second wave of AIDS in Sub-Saharan Africa. Oncologist 2013; 18:777-8. PubMed
  • Fojo AT, Bates SE, Chabner BA. Clinical trial results: Sharing results, speeding discoveries. Oncologist 2013; 18:779. PubMed
  • Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med 2012; 367:2150-3. PubMed
  • Raj A, Ko N, Battaglia TA, Chabner BA, Moy B. Patient navigation for underserved patients diagnosed with breast cancer. Oncologist 2012; 17:1027-31. PubMed
  • Chabner BA. That old devil moon. Oncologist 2012; 17:1349-50. PubMed
  • Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011; 364:1087-9. PubMed
  • Murphy JP, Chabner BA. Reflections on the knife edge. Oncologist 2011; 16:257-9. PubMed
  • Donelan K, Mailhot JR, Dutwin D, Barnicle K, Oo SA, Hobrecker K, Percac-Lima S, Chabner BA. Patient Perspectives of Clinical Care and Patient Navigation in Follow-up of Abnormal Mammography. J Gen Intern Med 2010. PubMed
  • Chabner BA. About Eli. Oncologist 2010; 15:329-31. PubMed
  • Chabner BA. New results will change the paradigm for phase I trials and drug approval. Oncologist 2010; 15:1023-5. PubMed
  • Chabner BA. Academia-pharma intersect: providing a broader perspective on drug development synergies between academia and industry. Oncologist 2010; 15:1-2. PubMed
  • Chong CR, Chabner BA. Mysterious metformin. Oncologist 2009; 14:1178-81. PubMed
  • Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459-68. PubMed
  • Donelan K,Hobrecker K,Schapira L,Mailhot JR,Goulart BH,Chabner BA. Medical interpreter knowledge of cancer and cancer clinical trials. Cancer 2009; 115:3283-92. PubMed
  • Chabner BA. Obituary. Cancer Sci 2009; 100:565-6. PubMed
  • Chabner BA. Ghost writers in the sky. Oncologist 2009; 14:199-200. PubMed
  • Chabner BA. The National Cancer Institute and its Director: worthy of our full support. Oncologist 2009; 14:108-9. PubMed
  • Schapira L,Gordon-Rowe L,Martignetti R,Washington D,Bartholomay M,Greenberg D,Lathan C,LaFrancesca J,Lynch T,Chabner B. Racism in the chemotherapy infusion unit: a nurse's story. Oncologist 2008; 13:1177-80. PubMed
  • Chabner BA. Dr. Joseph R. Bertino: a reflection. Oncologist 2008; 13:1034-5. PubMed
  • Chabner BA. Preserving the sacred bond: an audit must be performed. Oncologist 2008; 13:922. PubMed
  • Curt GA,Chabner BA. One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis? Oncologist 2008; 13:923-4. PubMed
  • Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. J Clin Oncol 2008; 26:2717-24. PubMed
  • Chabner BA. Smoke, then Fire: Lung Cancer Screening Studies Under Further Scrutiny. Oncologist 2008; 13:348-9. PubMed
  • Chabner BA. Conflict of interest: in the eye of the beholder? Oncologist 2008; 13:212-3. PubMed
  • Chabner B. Advances and challenges in the use of biomarkers in clinical trials. Clin Adv Hematol Oncol 2008; 6:42-3. PubMed
  • Novina CD, Chabner BA. RNA-Directed Therapy: The Next Step in the miRNA Revolution. Oncologist 2008; 13:1-3. PubMed
  • Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 2007; 13:6719-26. PubMed
  • Chabner BA, Ratain MJ. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control Clin Cancer Res 2007; 13:6540. PubMed
  • Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res 2007; 13:5232-7. PubMed
  • Chabner BA. Orange alert for oncologists. Oncologist 2007; 12:902-3. PubMed
  • Chabner B. Phase II cancer trials: out of control? Clin Cancer Res 2007; 13:2307-8. PubMed
  • Penson RT, Kyriakou H, Zuckerman D, Chabner BA, Lynch TJ. Teams: communication in multidisciplinary care. Oncologist 2006; 11:520-6. PubMed
  • Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ. Direct-to-consumer advertising in oncology. Oncologist 2006; 11:217-26. PubMed
  • Penson RT, Partridge RA, Rudd P, Seiden MV, Nelson JE, Chabner BA, Lynch TJ. Laughter: the best medicine? Oncologist 2005; 10:651-60. PubMed
  • Chabner BA, Murphy MJ. Breast cancer: a tale of two centuries: with implications for understanding cancer metastasis and cancer stem cell biology. Oncologist 2005; 10:369. PubMed
  • Wolpin BM, Chabner BA, Lynch TJ, Penson RT. Learning to cope: how far is too close? Oncologist 2005; 10:449-56. PubMed
  • Penson RT, Partridge RA, Shah MA, Giansiracusa D, Chabner BA, Lynch TJ. Fear of death. Oncologist 2005; 10:160-9. PubMed
  • Chabner BA, Roberts TG. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5:65-72. PubMed
  • Roberts TG, Chabner BA. Beyond fast track for drug approvals. N Engl J Med 2004; 351:501-5. PubMed
  • Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004; 10:3927-33. PubMed
  • Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004; 10:3885-96. PubMed
  • Zhu AX, Puchalski TA, Stanton VP, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer 2004; 3:225-34. PubMed
  • Penson RT, Talsania SH, Chabner BA, Lynch TJ. Help me help you: support groups in cancer therapy. Oncologist 2004; 9:217-25. PubMed
  • Roberts TG, Lynch TJ, Chabner BA. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol 2003; 21:3683-95. PubMed
  • Brugarolas J, Clark JW, Chabner B. Using "rationally designed drugs" rationally. Lancet 2003; 361:1758-9. PubMed
  • Penson RT, Fergus LA, Haston RJ, Clark JR, Demotses A, O'Connell JJ, Chabner BA, Lynch TJ. The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless. Oncologist 2003; 8:488-95. PubMed
  • Dias L, Chabner BA, Lynch TJ, Penson RT. Breaking bad news: a patient's perspective. Oncologist 2003; 8:587-96. PubMed
  • Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch TJ, Penson RT. Living as a cancer surpriser: a doctor tells his story. Oncologist 2003; 8:108-22. PubMed
  • Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99:2685-93. PubMed
  • Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99:2685-93.
  • Penson RT, Green KM, Chabner BA, Lynch TJ. When does the responsibility of our care end: bereavement. Oncologist 2002; 7:251-8. PubMed
  • Roberts TG, Lynch TJ, Chabner BA. Choosing chemotherapy for lung cancer based on cost: not yet. Oncologist 2002; 7:177-8. PubMed
  • Penson RT, Rauch PK, McAfee SL, Cashavelly BJ, Clair-Hayes K, Dahlin C, Green KM, Chabner BA, Lynch TJ. Between parent and child: negotiating cancer treatment in adolescents. Oncologist 2002; 7:154-62. PubMed
  • Penson RT, Benson RC, Parles K, Chabner BA, Lynch TJ. Virtual connections: Internet health care. Oncologist 2002; 7:555-68. PubMed
  • Knuti KA, Amrein PC, Chabner BA, Lynch TJ, Penson RT. Faith, identity, and leukemia: when blood products are not an option. Oncologist 2002; 7:371-80. PubMed
  • Penson RT, Svendsen SS, Chabner BA, Lynch TJ, Levinson W. Medical mistakes: a workshop on personal perspectives. Oncologist 2001; 6:92-9. PubMed
  • Penson RT, Castro CM, Seiden MV, Chabner BA, Lynch TJ. Complementary, alternative, integrative, or unconventional medicine? Oncologist 2001; 6:463-73. PubMed
  • Penson RT, Seiden MV, Chabner BA, Lynch TJ. Caring for colleagues. Oncologist 2001; 6:197-204. PubMed
  • Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18:3633-42. PubMed
  • Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ. Sexuality and cancer: conversation comfort zone. Oncologist 2000; 5:336-44. PubMed
  • Penson RT, Seiden MV, Shannon KM, Lubratovich ML, Roche M, Chabner BA, Lynch TJ. Communicating genetic risk: pros, cons, and counsel. Oncologist 2000; 5:152-61. PubMed
  • Krakauer EL, Penson RT, Truog RD, King LA, Chabner BA, Lynch TJ. Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect. Oncologist 2000; 5:53-62. PubMed
  • Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995; 13:1995-2004. PubMed
  • Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995; 13:1985-94. PubMed
  • Saikawa Y, Knight CB, Saikawa T, Page ST, Chabner BA, Elwood PC. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells. J Biol Chem 1993; 268:5293-301. PubMed